Tamoxifen 20 - Aaster Solutions

Tamoxifen citrate entered clinical history in the 1960s when ICI scientists redirected a failed contraceptive candidate toward breast cancer research. It was discovered that the compound could selectively block estrogen receptors, leading to tumor suppression in hormone-sensitive breast cancers. Approved in the U.S. in 1977 as Nolvadex, it revolutionized cancer care for women. Over time, its anti-estrogenic action led to widespread use in anabolic steroid cycles, where users relied on it to prevent estrogen-related side effects like gynecomastia.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Tamoxifen 20 by Aaster Solutions, consult with your doctor or healthcare professional.